Article

Key clinical point: Compared with the open gastrectomy, laparoscopic gastrectomy is associated with less intraoperative blood loss, shorter hospitalization time, and early postoperative exhaust in patients with gastric cancer.

Major finding: Patients in the laparoscopic vs open gastrectomy group had less intraoperative bleeding (standardized mean difference [SMD] −1.11; P  =  .0006), early postoperative exhaust (SMD −0.45; P  =  .0004), first postoperative feeding (SMD −0.45; P  =  .0004), and shorter postoperative hospital stay (SMD­ −0.97; P  =  .008), but had a longer operation time (SMD­ 0.65; P < .00001). There was no significant difference in the number of lymph nodes dissected (P  =  .45) and the incidence of complications after 30 days of surgery (P  =  .23) between the 2 groups.

Study details: These results are from a meta-analysis 11 studies including 1027 patients with gastric cancer who underwent laparoscopic or open gastrectomy.

Disclosures: This study was supported by Key Clinical Subject construction Program of Chongqing Medical University, China. The authors declared no conflicts of interest.

Source: Huang K et al. Effects of laparoscopic versus open surgery for advanced gastric cancer after neoadjuvant chemotherapy: A meta-analysis. J Healthc Eng. 2022;3255403 (Jun 18). Doi: 10.1155/2022/3255403

Key clinical point: Compared with the open gastrectomy, laparoscopic gastrectomy is associated with less intraoperative blood loss, shorter hospitalization time, and early postoperative exhaust in patients with gastric cancer.

Major finding: Patients in the laparoscopic vs open gastrectomy group had less intraoperative bleeding (standardized mean difference [SMD] −1.11; P  =  .0006), early postoperative exhaust (SMD −0.45; P  =  .0004), first postoperative feeding (SMD −0.45; P  =  .0004), and shorter postoperative hospital stay (SMD­ −0.97; P  =  .008), but had a longer operation time (SMD­ 0.65; P < .00001). There was no significant difference in the number of lymph nodes dissected (P  =  .45) and the incidence of complications after 30 days of surgery (P  =  .23) between the 2 groups.

Study details: These results are from a meta-analysis 11 studies including 1027 patients with gastric cancer who underwent laparoscopic or open gastrectomy.

Disclosures: This study was supported by Key Clinical Subject construction Program of Chongqing Medical University, China. The authors declared no conflicts of interest.

Source: Huang K et al. Effects of laparoscopic versus open surgery for advanced gastric cancer after neoadjuvant chemotherapy: A meta-analysis. J Healthc Eng. 2022;3255403 (Jun 18). Doi: 10.1155/2022/3255403

Key clinical point: Compared with the open gastrectomy, laparoscopic gastrectomy is associated with less intraoperative blood loss, shorter hospitalization time, and early postoperative exhaust in patients with gastric cancer.

Major finding: Patients in the laparoscopic vs open gastrectomy group had less intraoperative bleeding (standardized mean difference [SMD] −1.11; P  =  .0006), early postoperative exhaust (SMD −0.45; P  =  .0004), first postoperative feeding (SMD −0.45; P  =  .0004), and shorter postoperative hospital stay (SMD­ −0.97; P  =  .008), but had a longer operation time (SMD­ 0.65; P < .00001). There was no significant difference in the number of lymph nodes dissected (P  =  .45) and the incidence of complications after 30 days of surgery (P  =  .23) between the 2 groups.

Study details: These results are from a meta-analysis 11 studies including 1027 patients with gastric cancer who underwent laparoscopic or open gastrectomy.

Disclosures: This study was supported by Key Clinical Subject construction Program of Chongqing Medical University, China. The authors declared no conflicts of interest.

Source: Huang K et al. Effects of laparoscopic versus open surgery for advanced gastric cancer after neoadjuvant chemotherapy: A meta-analysis. J Healthc Eng. 2022;3255403 (Jun 18). Doi: 10.1155/2022/3255403

Key clinical point: In patients with advanced gastric cancer, surgical vs nonsurgical palliation is associated with a significantly shorter overall survival (OS) and a significantly higher hazard of mortality.

Major finding: The use of surgical palliation declined significantly during 2004-2015 (P < .0001). The median OS was significantly longer in patients who received nonsurgical vs surgical palliation (6.0 vs 3.6 months; P < .001). Surgical vs nonsurgical palliation was associated with a significantly higher risk for mortality (adjusted hazard ratio 1.20; P < .001).

Study details: A retrospective study of 6829 patients with clinical stage IV gastric cancer from the National Cancer Database (2004-2015) who received surgical or nonsurgical palliation.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Nohria A et al. Outcomes after surgical palliation of patients with gastric cancer. J Surg Res. 2022;279:304-311 (Jul 6). Doi: 10.1016/j.jss.2022.06.018

Key clinical point: In patients with advanced gastric cancer, surgical vs nonsurgical palliation is associated with a significantly shorter overall survival (OS) and a significantly higher hazard of mortality.

Major finding: The use of surgical palliation declined significantly during 2004-2015 (P < .0001). The median OS was significantly longer in patients who received nonsurgical vs surgical palliation (6.0 vs 3.6 months; P < .001). Surgical vs nonsurgical palliation was associated with a significantly higher risk for mortality (adjusted hazard ratio 1.20; P < .001).

Study details: A retrospective study of 6829 patients with clinical stage IV gastric cancer from the National Cancer Database (2004-2015) who received surgical or nonsurgical palliation.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Nohria A et al. Outcomes after surgical palliation of patients with gastric cancer. J Surg Res. 2022;279:304-311 (Jul 6). Doi: 10.1016/j.jss.2022.06.018

Key clinical point: In patients with advanced gastric cancer, surgical vs nonsurgical palliation is associated with a significantly shorter overall survival (OS) and a significantly higher hazard of mortality.

Major finding: The use of surgical palliation declined significantly during 2004-2015 (P < .0001). The median OS was significantly longer in patients who received nonsurgical vs surgical palliation (6.0 vs 3.6 months; P < .001). Surgical vs nonsurgical palliation was associated with a significantly higher risk for mortality (adjusted hazard ratio 1.20; P < .001).

Study details: A retrospective study of 6829 patients with clinical stage IV gastric cancer from the National Cancer Database (2004-2015) who received surgical or nonsurgical palliation.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Nohria A et al. Outcomes after surgical palliation of patients with gastric cancer. J Surg Res. 2022;279:304-311 (Jul 6). Doi: 10.1016/j.jss.2022.06.018

Key clinical point: Mediterranean diet is associated with a lower risk of developing gastric cancer.

Major finding: The Mediterranean dietary pattern, which includes a diet rich in fresh fruits, vegetables, milk, yogurt, lentils, and olive oil, was associated with a significantly lower risk for gastric cancer in the third (adjusted odds ratio [aOR] 0.394; 95% CI 0.211-0.736) and fourth (aOR 0.212; 95% CI 0.107-0.419) quartiles. The Prudent, Unhealthy, and High-fruit diets did not show any association with the risk for gastric cancer.

Study details: A case-control study of 172 patients with incident gastric cancer and 314 controls. Four dietary patterns were identified and analyzed: Mediterranean, Prudent, Unhealthy, and High-fruit dietary patterns.

Disclosures: This study was funded by Hashemite University, Jordan. The authors declared no competing interests.

Source: Tayyem R et al. Mediterranean dietary pattern is associated with lower odds of gastric cancer: A case–control study. Cancer Manag Res. 2022;14:2017-2029 (Jun 17). Doi: 10.2147/CMAR.S360468

Key clinical point: Mediterranean diet is associated with a lower risk of developing gastric cancer.

Major finding: The Mediterranean dietary pattern, which includes a diet rich in fresh fruits, vegetables, milk, yogurt, lentils, and olive oil, was associated with a significantly lower risk for gastric cancer in the third (adjusted odds ratio [aOR] 0.394; 95% CI 0.211-0.736) and fourth (aOR 0.212; 95% CI 0.107-0.419) quartiles. The Prudent, Unhealthy, and High-fruit diets did not show any association with the risk for gastric cancer.

Study details: A case-control study of 172 patients with incident gastric cancer and 314 controls. Four dietary patterns were identified and analyzed: Mediterranean, Prudent, Unhealthy, and High-fruit dietary patterns.

Disclosures: This study was funded by Hashemite University, Jordan. The authors declared no competing interests.

Source: Tayyem R et al. Mediterranean dietary pattern is associated with lower odds of gastric cancer: A case–control study. Cancer Manag Res. 2022;14:2017-2029 (Jun 17). Doi: 10.2147/CMAR.S360468

Key clinical point: Mediterranean diet is associated with a lower risk of developing gastric cancer.

Major finding: The Mediterranean dietary pattern, which includes a diet rich in fresh fruits, vegetables, milk, yogurt, lentils, and olive oil, was associated with a significantly lower risk for gastric cancer in the third (adjusted odds ratio [aOR] 0.394; 95% CI 0.211-0.736) and fourth (aOR 0.212; 95% CI 0.107-0.419) quartiles. The Prudent, Unhealthy, and High-fruit diets did not show any association with the risk for gastric cancer.

Study details: A case-control study of 172 patients with incident gastric cancer and 314 controls. Four dietary patterns were identified and analyzed: Mediterranean, Prudent, Unhealthy, and High-fruit dietary patterns.

Disclosures: This study was funded by Hashemite University, Jordan. The authors declared no competing interests.

Source: Tayyem R et al. Mediterranean dietary pattern is associated with lower odds of gastric cancer: A case–control study. Cancer Manag Res. 2022;14:2017-2029 (Jun 17). Doi: 10.2147/CMAR.S360468

Key clinical point: Dietary iron shows an inverse association with the risk for gastric cancer irrespective of cancer subsite and histological type.

Major finding: Dietary iron intake was inversely associated with the risk for gastric cancer (per quartile odds ratio [OR] 0.88; 95% CI 0.83-0.93). The association (per quartile) was significant for cardia (OR 0.85; 95% CI 0.77-0.94) and noncardia (OR 0.87; 95% CI 0.81-0.94) gastric cancer and diffuse (OR,0.79; 95% CI 0.69-0.89) and intestinal (OR 0.88; 95% CI 0.79-0.98) type.

Study details: An analysis of pooled data from 11 case-control studies including 4658 participants with gastric cancer and 12,247 control participants from the Stomach Cancer Pooling Project.

Disclosures: This study was supported by AIRC Foundation for Cancer Research, Italy. The authors declared no conflicts of interest.

Source: Collatuzzo G et al. Inverse association between dietary iron intake and gastric cancer: A pooled analysis of case-control studies of the stop consortium. Nutrients. 2022;14(12):2555 (Jun 20). Doi: 10.3390/nu14122555

Key clinical point: Dietary iron shows an inverse association with the risk for gastric cancer irrespective of cancer subsite and histological type.

Major finding: Dietary iron intake was inversely associated with the risk for gastric cancer (per quartile odds ratio [OR] 0.88; 95% CI 0.83-0.93). The association (per quartile) was significant for cardia (OR 0.85; 95% CI 0.77-0.94) and noncardia (OR 0.87; 95% CI 0.81-0.94) gastric cancer and diffuse (OR,0.79; 95% CI 0.69-0.89) and intestinal (OR 0.88; 95% CI 0.79-0.98) type.

Study details: An analysis of pooled data from 11 case-control studies including 4658 participants with gastric cancer and 12,247 control participants from the Stomach Cancer Pooling Project.

Disclosures: This study was supported by AIRC Foundation for Cancer Research, Italy. The authors declared no conflicts of interest.

Source: Collatuzzo G et al. Inverse association between dietary iron intake and gastric cancer: A pooled analysis of case-control studies of the stop consortium. Nutrients. 2022;14(12):2555 (Jun 20). Doi: 10.3390/nu14122555

Key clinical point: Dietary iron shows an inverse association with the risk for gastric cancer irrespective of cancer subsite and histological type.

Major finding: Dietary iron intake was inversely associated with the risk for gastric cancer (per quartile odds ratio [OR] 0.88; 95% CI 0.83-0.93). The association (per quartile) was significant for cardia (OR 0.85; 95% CI 0.77-0.94) and noncardia (OR 0.87; 95% CI 0.81-0.94) gastric cancer and diffuse (OR,0.79; 95% CI 0.69-0.89) and intestinal (OR 0.88; 95% CI 0.79-0.98) type.

Study details: An analysis of pooled data from 11 case-control studies including 4658 participants with gastric cancer and 12,247 control participants from the Stomach Cancer Pooling Project.

Disclosures: This study was supported by AIRC Foundation for Cancer Research, Italy. The authors declared no conflicts of interest.

Source: Collatuzzo G et al. Inverse association between dietary iron intake and gastric cancer: A pooled analysis of case-control studies of the stop consortium. Nutrients. 2022;14(12):2555 (Jun 20). Doi: 10.3390/nu14122555

Key clinical point: Cisplatin and oxaliplatin are both suitable as a part of the systemic therapy for resectable gastric cancer.

Major finding: Patients receiving epirubicin+cisplatin+capecitabine (ECX) and those receiving epirubicin+oxaliplatin+capecitabine (EOX) had comparable 5-year overall survival (42% vs 47%; P  =  .303), preoperative (67% vs 60%; P  =  .105) and postoperative (60% vs 51%; P  =  .266) severe (grades 3-5) toxicity, and complete or near-complete pathological response (21% vs 15%; P  =  .126) rates.

Study details: This post hoc analysis included 781 adult patients with resectable gastric cancer from the CRITICS trial who received preoperative ECX (n = 632) or EOX (n = 149), of which 636 and 233 received potentially curative surgery and postoperative chemotherapy, respectively.

Disclosures: The CRITICS trial was sponsored by the Dutch Cancer Society, Dutch Colorectal Cancer Group, and Hoffmann-La Roche; this analysis required no additional funding. The authors declared no conflicts of interest.

Source: Slagter AE et al. Triplet chemotherapy with cisplatin versus oxaliplatin in the CRITICS trial: Treatment compliance, toxicity, outcomes and quality of life in patients with resectable gastric cancer. Cancers (Basel). 2022;14(12):2963 (Jun 15). Doi: 10.3390/cancers14122963

Key clinical point: Cisplatin and oxaliplatin are both suitable as a part of the systemic therapy for resectable gastric cancer.

Major finding: Patients receiving epirubicin+cisplatin+capecitabine (ECX) and those receiving epirubicin+oxaliplatin+capecitabine (EOX) had comparable 5-year overall survival (42% vs 47%; P  =  .303), preoperative (67% vs 60%; P  =  .105) and postoperative (60% vs 51%; P  =  .266) severe (grades 3-5) toxicity, and complete or near-complete pathological response (21% vs 15%; P  =  .126) rates.

Study details: This post hoc analysis included 781 adult patients with resectable gastric cancer from the CRITICS trial who received preoperative ECX (n = 632) or EOX (n = 149), of which 636 and 233 received potentially curative surgery and postoperative chemotherapy, respectively.

Disclosures: The CRITICS trial was sponsored by the Dutch Cancer Society, Dutch Colorectal Cancer Group, and Hoffmann-La Roche; this analysis required no additional funding. The authors declared no conflicts of interest.

Source: Slagter AE et al. Triplet chemotherapy with cisplatin versus oxaliplatin in the CRITICS trial: Treatment compliance, toxicity, outcomes and quality of life in patients with resectable gastric cancer. Cancers (Basel). 2022;14(12):2963 (Jun 15). Doi: 10.3390/cancers14122963

Key clinical point: Cisplatin and oxaliplatin are both suitable as a part of the systemic therapy for resectable gastric cancer.

Major finding: Patients receiving epirubicin+cisplatin+capecitabine (ECX) and those receiving epirubicin+oxaliplatin+capecitabine (EOX) had comparable 5-year overall survival (42% vs 47%; P  =  .303), preoperative (67% vs 60%; P  =  .105) and postoperative (60% vs 51%; P  =  .266) severe (grades 3-5) toxicity, and complete or near-complete pathological response (21% vs 15%; P  =  .126) rates.

Study details: This post hoc analysis included 781 adult patients with resectable gastric cancer from the CRITICS trial who received preoperative ECX (n = 632) or EOX (n = 149), of which 636 and 233 received potentially curative surgery and postoperative chemotherapy, respectively.

Disclosures: The CRITICS trial was sponsored by the Dutch Cancer Society, Dutch Colorectal Cancer Group, and Hoffmann-La Roche; this analysis required no additional funding. The authors declared no conflicts of interest.

Source: Slagter AE et al. Triplet chemotherapy with cisplatin versus oxaliplatin in the CRITICS trial: Treatment compliance, toxicity, outcomes and quality of life in patients with resectable gastric cancer. Cancers (Basel). 2022;14(12):2963 (Jun 15). Doi: 10.3390/cancers14122963

Key clinical point: In patients with locally advanced gastric cancer (LAGC), neoadjuvant chemotherapy (NACT) followed by laparoscopic gastrectomy (LG) vs upfront LG is associated with a lower rate of severe postoperative complications and improved survival.

Major finding: Grade ≥ 3 severe postoperative complication rate was significantly lower in the NACT-LG vs upfront LG group (0% vs 17.1%; P  =  .001). The postoperative complication-related death rate was 0% in the NACT-LG group vs 2.9% in the upfront LG group. NACT-LG vs upfront LG was associated with improved disease-free survival (14.4% vs 5.7%; P  =  .0299) and overall survival (34.1% vs 8.6%; P  =  .0061) at 3 years.

Study details: This was a retrospective study of 76 consecutive patients with LAGC who received either LG following NACT or upfront LG between March 2013 and October 2018.

Disclosures: This study did not receive any funding. The authors declare no competing interests.

Source: Liu L et al. The safety and efficacy of laparoscopic gastrectomy for patients with locally advanced gastric cancer following neoadjuvant chemotherapy. Sci Rep. 2022;12:10384 (Jun 20). Doi: 10.1038/s41598-022-14717-6

Key clinical point: In patients with locally advanced gastric cancer (LAGC), neoadjuvant chemotherapy (NACT) followed by laparoscopic gastrectomy (LG) vs upfront LG is associated with a lower rate of severe postoperative complications and improved survival.

Major finding: Grade ≥ 3 severe postoperative complication rate was significantly lower in the NACT-LG vs upfront LG group (0% vs 17.1%; P  =  .001). The postoperative complication-related death rate was 0% in the NACT-LG group vs 2.9% in the upfront LG group. NACT-LG vs upfront LG was associated with improved disease-free survival (14.4% vs 5.7%; P  =  .0299) and overall survival (34.1% vs 8.6%; P  =  .0061) at 3 years.

Study details: This was a retrospective study of 76 consecutive patients with LAGC who received either LG following NACT or upfront LG between March 2013 and October 2018.

Disclosures: This study did not receive any funding. The authors declare no competing interests.

Source: Liu L et al. The safety and efficacy of laparoscopic gastrectomy for patients with locally advanced gastric cancer following neoadjuvant chemotherapy. Sci Rep. 2022;12:10384 (Jun 20). Doi: 10.1038/s41598-022-14717-6

Key clinical point: In patients with locally advanced gastric cancer (LAGC), neoadjuvant chemotherapy (NACT) followed by laparoscopic gastrectomy (LG) vs upfront LG is associated with a lower rate of severe postoperative complications and improved survival.

Major finding: Grade ≥ 3 severe postoperative complication rate was significantly lower in the NACT-LG vs upfront LG group (0% vs 17.1%; P  =  .001). The postoperative complication-related death rate was 0% in the NACT-LG group vs 2.9% in the upfront LG group. NACT-LG vs upfront LG was associated with improved disease-free survival (14.4% vs 5.7%; P  =  .0299) and overall survival (34.1% vs 8.6%; P  =  .0061) at 3 years.

Study details: This was a retrospective study of 76 consecutive patients with LAGC who received either LG following NACT or upfront LG between March 2013 and October 2018.

Disclosures: This study did not receive any funding. The authors declare no competing interests.

Source: Liu L et al. The safety and efficacy of laparoscopic gastrectomy for patients with locally advanced gastric cancer following neoadjuvant chemotherapy. Sci Rep. 2022;12:10384 (Jun 20). Doi: 10.1038/s41598-022-14717-6

Key clinical point: Low body mass index (BMI) increased the risk for gastric cancer in men and women, whereas high fasting glucose levels slightly increased the risk in women but not in men.

Major finding: Low BMI (<18.5 kg/m²) increased the risk for gastric cancer in both men (adjusted odds ratio [aOR] 1.39; P < .001) and women (aOR 1.48; P < .001). High fasting glucose levels (≥126 mg/dL) slightly elevated gastric cancer risk in women (aOR 1.19; P < .001) but not in men.

Study details: This prospective, population-based cohort study included 5174 million individuals (men, 43.1%) who underwent national gastric cancer screening and were followed up for 9 years.

Disclosures: This study was funded by the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea; and others. The authors declared no conflicts of interest.

Source: Nam SY et al. Sex-specific effect of body mass index and fasting glucose on gastric cancer risk and all causes mortality; a cohort study of 5.17 million. Int J Obes. 2022 (Jun 10). Doi: 10.1038/s41366-022-01161-9

Key clinical point: Low body mass index (BMI) increased the risk for gastric cancer in men and women, whereas high fasting glucose levels slightly increased the risk in women but not in men.

Major finding: Low BMI (<18.5 kg/m²) increased the risk for gastric cancer in both men (adjusted odds ratio [aOR] 1.39; P < .001) and women (aOR 1.48; P < .001). High fasting glucose levels (≥126 mg/dL) slightly elevated gastric cancer risk in women (aOR 1.19; P < .001) but not in men.

Study details: This prospective, population-based cohort study included 5174 million individuals (men, 43.1%) who underwent national gastric cancer screening and were followed up for 9 years.

Disclosures: This study was funded by the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea; and others. The authors declared no conflicts of interest.

Source: Nam SY et al. Sex-specific effect of body mass index and fasting glucose on gastric cancer risk and all causes mortality; a cohort study of 5.17 million. Int J Obes. 2022 (Jun 10). Doi: 10.1038/s41366-022-01161-9

Key clinical point: Low body mass index (BMI) increased the risk for gastric cancer in men and women, whereas high fasting glucose levels slightly increased the risk in women but not in men.

Major finding: Low BMI (<18.5 kg/m²) increased the risk for gastric cancer in both men (adjusted odds ratio [aOR] 1.39; P < .001) and women (aOR 1.48; P < .001). High fasting glucose levels (≥126 mg/dL) slightly elevated gastric cancer risk in women (aOR 1.19; P < .001) but not in men.

Study details: This prospective, population-based cohort study included 5174 million individuals (men, 43.1%) who underwent national gastric cancer screening and were followed up for 9 years.

Disclosures: This study was funded by the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea; and others. The authors declared no conflicts of interest.

Source: Nam SY et al. Sex-specific effect of body mass index and fasting glucose on gastric cancer risk and all causes mortality; a cohort study of 5.17 million. Int J Obes. 2022 (Jun 10). Doi: 10.1038/s41366-022-01161-9

Key clinical point: Microsatellite instability (MSI)-high locally advanced gastric cancer is less likely to display a pathologic response to chemotherapy but is associated with better survival than microsatellite-stable (MSS) cancer.

Major finding: In patients treated with chemotherapy, MSI-high vs MSS tumors were associated with a significantly better overall survival (adjusted hazard ratio [aHR] 0.53; P  =  .047) and disease-specific survival (aHR 0.24; P  =  .002) and a lower pathological chemotherapy response rate (0% vs 16%; P < .001).

Study details: This retrospective cohort study included 535 patients with primary, locally advanced gastric cancer who underwent surgery alone or in conjunction with neoadjuvant, perioperative, or adjuvant chemotherapy, of which 82 patients had an MSI-high tumor.

Disclosures: This study was supported by a US National Cancer Institute Cancer Center Support Grant. The authors declared no conflicts of interest.

Source: Vos EL et al. Survival of locally advanced MSI-high gastric cancer patients treated with perioperative chemotherapy: A retrospective cohort study. Ann Surg. 2022 (Jun 29). Doi: 10.1097/SLA.0000000000005501

Key clinical point: Microsatellite instability (MSI)-high locally advanced gastric cancer is less likely to display a pathologic response to chemotherapy but is associated with better survival than microsatellite-stable (MSS) cancer.

Major finding: In patients treated with chemotherapy, MSI-high vs MSS tumors were associated with a significantly better overall survival (adjusted hazard ratio [aHR] 0.53; P  =  .047) and disease-specific survival (aHR 0.24; P  =  .002) and a lower pathological chemotherapy response rate (0% vs 16%; P < .001).

Study details: This retrospective cohort study included 535 patients with primary, locally advanced gastric cancer who underwent surgery alone or in conjunction with neoadjuvant, perioperative, or adjuvant chemotherapy, of which 82 patients had an MSI-high tumor.

Disclosures: This study was supported by a US National Cancer Institute Cancer Center Support Grant. The authors declared no conflicts of interest.

Source: Vos EL et al. Survival of locally advanced MSI-high gastric cancer patients treated with perioperative chemotherapy: A retrospective cohort study. Ann Surg. 2022 (Jun 29). Doi: 10.1097/SLA.0000000000005501

Key clinical point: Microsatellite instability (MSI)-high locally advanced gastric cancer is less likely to display a pathologic response to chemotherapy but is associated with better survival than microsatellite-stable (MSS) cancer.

Major finding: In patients treated with chemotherapy, MSI-high vs MSS tumors were associated with a significantly better overall survival (adjusted hazard ratio [aHR] 0.53; P  =  .047) and disease-specific survival (aHR 0.24; P  =  .002) and a lower pathological chemotherapy response rate (0% vs 16%; P < .001).

Study details: This retrospective cohort study included 535 patients with primary, locally advanced gastric cancer who underwent surgery alone or in conjunction with neoadjuvant, perioperative, or adjuvant chemotherapy, of which 82 patients had an MSI-high tumor.

Disclosures: This study was supported by a US National Cancer Institute Cancer Center Support Grant. The authors declared no conflicts of interest.

Source: Vos EL et al. Survival of locally advanced MSI-high gastric cancer patients treated with perioperative chemotherapy: A retrospective cohort study. Ann Surg. 2022 (Jun 29). Doi: 10.1097/SLA.0000000000005501

Key clinical point: Compared with adjuvant chemotherapy, adjuvant chemoradiotherapy is associated with improved survival in patients with resectable advanced gastric cancer.

Major finding: Adjuvant chemoradiotherapy significantly improved the overall survival (pooled hazard ratio [HR] 0.84; 95% CI 0.71-0.99) and disease-free survival (pooled HR 0.76; 95% CI 0.66-0.89). Neutropenia was the most common hematological toxicity. Nausea/vomiting was the most common gastrointestinal adverse event. Adjuvant chemoradiotherapy was associated with a higher risk for neutropenia (odds ratio 1.71; 95% CI 1.40-2.10).

Study details: This was a meta-analysis of 28 studies including 20,220 patients with resectable gastric cancer who received chemotherapy or chemoradiotherapy as adjuvant treatment.

Disclosures: This meta-analysis was supported by the Natural Science Foundation of Liaoning Province and Shenyang Science and Technology Plan, China. The authors declared no conflicts of interest.

Source: Lu H et al. Effect of chemoradiotherapy on the survival of resectable gastric cancer patients: A systematic review and meta-analysis. Ann Surg Oncol. 2022 (Jun 20). Doi: 10.1245/s10434-022-12005-1

Key clinical point: Compared with adjuvant chemotherapy, adjuvant chemoradiotherapy is associated with improved survival in patients with resectable advanced gastric cancer.

Major finding: Adjuvant chemoradiotherapy significantly improved the overall survival (pooled hazard ratio [HR] 0.84; 95% CI 0.71-0.99) and disease-free survival (pooled HR 0.76; 95% CI 0.66-0.89). Neutropenia was the most common hematological toxicity. Nausea/vomiting was the most common gastrointestinal adverse event. Adjuvant chemoradiotherapy was associated with a higher risk for neutropenia (odds ratio 1.71; 95% CI 1.40-2.10).

Study details: This was a meta-analysis of 28 studies including 20,220 patients with resectable gastric cancer who received chemotherapy or chemoradiotherapy as adjuvant treatment.

Disclosures: This meta-analysis was supported by the Natural Science Foundation of Liaoning Province and Shenyang Science and Technology Plan, China. The authors declared no conflicts of interest.

Source: Lu H et al. Effect of chemoradiotherapy on the survival of resectable gastric cancer patients: A systematic review and meta-analysis. Ann Surg Oncol. 2022 (Jun 20). Doi: 10.1245/s10434-022-12005-1

Key clinical point: Compared with adjuvant chemotherapy, adjuvant chemoradiotherapy is associated with improved survival in patients with resectable advanced gastric cancer.

Major finding: Adjuvant chemoradiotherapy significantly improved the overall survival (pooled hazard ratio [HR] 0.84; 95% CI 0.71-0.99) and disease-free survival (pooled HR 0.76; 95% CI 0.66-0.89). Neutropenia was the most common hematological toxicity. Nausea/vomiting was the most common gastrointestinal adverse event. Adjuvant chemoradiotherapy was associated with a higher risk for neutropenia (odds ratio 1.71; 95% CI 1.40-2.10).

Study details: This was a meta-analysis of 28 studies including 20,220 patients with resectable gastric cancer who received chemotherapy or chemoradiotherapy as adjuvant treatment.

Disclosures: This meta-analysis was supported by the Natural Science Foundation of Liaoning Province and Shenyang Science and Technology Plan, China. The authors declared no conflicts of interest.

Source: Lu H et al. Effect of chemoradiotherapy on the survival of resectable gastric cancer patients: A systematic review and meta-analysis. Ann Surg Oncol. 2022 (Jun 20). Doi: 10.1245/s10434-022-12005-1

Key clinical point: Anti-programmed cell death-1 (anti-PD-1) antibodies plus regorafenib or lenvatinib showed promising efficacy in patients with advanced gastric cancer (AGC) independent of the liver metastasis status.

Major finding: At a median 14-month follow-up, patients with vs without liver metastasis had a nonsignificant difference in median progression-free survival (7.8 vs 6.9 months; hazard ratio [HR] 0.817; P  =  .4813), median overall survival (15.6 vs 15.5 months; HR 0.723; P  =  .3398), and objective response rate (46% vs 69%; P  =  .0938).

Study details: This study analyzed combined efficacy outcomes in 54 patients with AGC and with (n = 28) or without (n = 26) liver metastasis from the phase 1b REGONIVO and phase 2 LENPEM trials who received regorafenib+nivolumab or lenvatinib+pembrolizumab.

Disclosures: These trials were sponsored by Bayer Healthcare Pharmaceuticals Inc., Ono Pharmaceuticals, and Merck Sharp & Dohme (MSD). Some authors declared receiving grants, research support, personal fees, or advisory or lecture fees from various sources, including Bayer, Ono, and MSD.

Source: Yukami H et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res. 2022 (Jul 8). Doi: 10.1158/1078-0432.CCR-22-0630

Key clinical point: Anti-programmed cell death-1 (anti-PD-1) antibodies plus regorafenib or lenvatinib showed promising efficacy in patients with advanced gastric cancer (AGC) independent of the liver metastasis status.

Major finding: At a median 14-month follow-up, patients with vs without liver metastasis had a nonsignificant difference in median progression-free survival (7.8 vs 6.9 months; hazard ratio [HR] 0.817; P  =  .4813), median overall survival (15.6 vs 15.5 months; HR 0.723; P  =  .3398), and objective response rate (46% vs 69%; P  =  .0938).

Study details: This study analyzed combined efficacy outcomes in 54 patients with AGC and with (n = 28) or without (n = 26) liver metastasis from the phase 1b REGONIVO and phase 2 LENPEM trials who received regorafenib+nivolumab or lenvatinib+pembrolizumab.

Disclosures: These trials were sponsored by Bayer Healthcare Pharmaceuticals Inc., Ono Pharmaceuticals, and Merck Sharp & Dohme (MSD). Some authors declared receiving grants, research support, personal fees, or advisory or lecture fees from various sources, including Bayer, Ono, and MSD.

Source: Yukami H et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res. 2022 (Jul 8). Doi: 10.1158/1078-0432.CCR-22-0630

Key clinical point: Anti-programmed cell death-1 (anti-PD-1) antibodies plus regorafenib or lenvatinib showed promising efficacy in patients with advanced gastric cancer (AGC) independent of the liver metastasis status.

Major finding: At a median 14-month follow-up, patients with vs without liver metastasis had a nonsignificant difference in median progression-free survival (7.8 vs 6.9 months; hazard ratio [HR] 0.817; P  =  .4813), median overall survival (15.6 vs 15.5 months; HR 0.723; P  =  .3398), and objective response rate (46% vs 69%; P  =  .0938).

Study details: This study analyzed combined efficacy outcomes in 54 patients with AGC and with (n = 28) or without (n = 26) liver metastasis from the phase 1b REGONIVO and phase 2 LENPEM trials who received regorafenib+nivolumab or lenvatinib+pembrolizumab.

Disclosures: These trials were sponsored by Bayer Healthcare Pharmaceuticals Inc., Ono Pharmaceuticals, and Merck Sharp & Dohme (MSD). Some authors declared receiving grants, research support, personal fees, or advisory or lecture fees from various sources, including Bayer, Ono, and MSD.

Source: Yukami H et al. Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials. Clin Cancer Res. 2022 (Jul 8). Doi: 10.1158/1078-0432.CCR-22-0630